Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium Inc. (EQ) is a clinical-stage biotechnology company pioneering therapies for severe autoimmune and inflammatory disorders. This news hub provides investors and stakeholders with timely updates on EQ's scientific advancements, regulatory milestones, and corporate developments.
Access curated press releases and analysis covering key areas including clinical trial results, regulatory communications, research partnerships, and financial performance updates. Our repository simplifies tracking of EQ's novel therapeutic candidates like itolizumab (anti-CD6) and cytokine inhibitors in development.
Bookmark this page for streamlined monitoring of Equillium's progress in addressing conditions such as graft-versus-host disease and lupus nephritis through immunomodulatory approaches. Return regularly for verified updates directly from company filings and authorized sources.
Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. have mutually terminated their merger agreement, originally aimed at enhancing cash reserves. CEO Bruce Steel stated that a recent partnership with Ono Pharmaceutical will extend Equillium's financial runway into 2025, allowing focus on its pipeline of multi-cytokine inhibitors. The strategic shift emphasizes confidence in its clinical programs, including EQ101 and Itolizumab, which target severe autoimmune disorders. Further details can be found in Equillium's Current Report on Form 8-K.
Equillium, Inc. (NASDAQ: EQ) announced the initiation of a Phase 2 clinical study of itolizumab in collaboration with Biocon Limited for treating ulcerative colitis (UC) in India. This double-blinded, placebo-controlled trial aims to evaluate the safety and efficacy of itolizumab compared to adalimumab in biologics-naïve patients. The study will enroll up to 90 patients and is designed to provide insights into itolizumab's potential benefits. Itolizumab, a first-in-class anti-CD6 monoclonal antibody, has shown promise in earlier studies on severe acute graft-versus-host disease.
Equillium, Inc. (Nasdaq: EQ) announced positive interim results from the EQUALISE study of itolizumab in lupus nephritis, with 83% of patients achieving a complete or partial response and 67% showing over 80% reduction in urine protein creatinine ratio by week 28. The company also confirmed the acquisition of Metacrine, expected to add $35 million in cash to its balance sheet, extending its operating runway into 2024. Additionally, Equillium initiated Phase 2 and Phase 1 studies for EQ101 and EQ102, respectively, targeting alopecia areata and celiac disease.
Equillium, Inc. (Nasdaq: EQ) presented key research at ACR Convergence, indicating that urinary soluble ALCAM (sALCAM) may serve as a biomarker for disease severity in lupus nephritis (LN), potentially aiding in treatment response assessment. This study aligns urinary ALCAM levels with existing measures of LN, suggesting a less invasive alternative to kidney biopsies. Dr. Maple Fung highlighted its significance for patient monitoring. Itolizumab, Equillium's first-in-class monoclonal antibody, targets the CD6-ALCAM pathway and is currently undergoing clinical studies for its effectiveness in treating severe autoimmune disorders.
Equillium has launched a Phase 2 proof-of-concept study for EQ101 targeting alopecia areata, a common autoimmune condition. This open-label trial will involve approximately 30 adult subjects in Australia over 24 weeks, assessing efficacy, safety, tolerability, and pharmacokinetics. EQ101 inhibits key cytokines IL-2, IL-9, and IL-15, potentially offering a more selective treatment than current options. Previous studies indicated EQ101's safety and effectiveness in related conditions. The study's results are anticipated in 2023, marking a significant advancement in Equillium's pipeline.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, announced its participation in the Stifel Healthcare Conference and the Jefferies London Healthcare Conference. Company management will present an overview of their clinical assets and discuss upcoming milestones. The Stifel conference is set for November 15 at Lotte New York Place Hotel, while the Jefferies conference will occur on November 17 in London. Webcast access will be available on their website, with archived replays for 90 days.
Equillium presented data on its novel Multi-Cytokine Inhibitor EQ101 for treating alopecia areata at the 6th Annual Dermatology Drug Development Summit. The presentation, made by Dr. Stephen Connelly, highlighted EQ101's selective targeting of IL-2, IL-9, and IL-15 with a favorable safety profile. A Phase 2 study is set to initiate in Q4 2022, aiming to evaluate its efficacy compared to other treatments. EQ101 demonstrated superior hair regrowth compared to ruxolitinib and has previously shown promise in cutaneous T cell lymphoma.
Equillium, Inc. (Nasdaq: EQ) announced the initiation of a Phase 1 study for its investigational drug EQ102, targeting celiac disease. The study involves up to 64 healthy volunteers and aims to evaluate safety and tolerability after administering single and multiple ascending doses. EQ102 is designed to inhibit cytokines IL-15 and IL-21, which are implicated in gastrointestinal inflammation. The CEO highlighted this as a significant milestone, with initial clinical data expected next year. Celiac disease has over 50 million global incidences and currently lacks effective treatments.
Equillium, Inc. (Nasdaq: EQ) presented promising data on its multi-cytokine inhibitors, EQ101 and EQ102, at the La Jolla Immunology Conference. The research indicates that these inhibitors effectively reduce the activity of cytotoxic T lymphocytes and natural killer cells, which are pivotal in autoimmune diseases.
EQ101 and EQ102 demonstrated approximately 50% and 40% reductions in CD4 and CD8 T cell proliferation, respectively. The company plans to initiate a Phase 2 study for EQ101 in alopecia areata and a Phase 1 study for EQ102 in healthy volunteers by year-end 2022.
